Tokai University has granted BioMedCore Inc. (“BMC”) an exclusive license on its patent “Liposome having oligosaccharide on the surface” and related technologies that the University acquired as a result of glycotechnological research for the purpose of jointly developing medicinal products. The University conducts continuous research and provides its research facilities while BMC undertakes the development of an adjuvant for induction of Th1 immune response (including cancer vaccines, etc.) using these technologies.

Joint Research Topics

・Development of GMP manufacturing process for medical nanotargeting devices by Tokai University & BMC

・Research and development on human medicinal products

Patents

・ “Liposome having oligosaccharide on the surface”

・ “Improved sugar-coated Liposome composition”

Features of the Technology

・Oligomannose-coated liposomes bind with glyco-receptors on the surface of macrophages and dendritic cells (DCs) and are selectively taken up by cells after which they enter the lymphoid tissue (macrophage delivery system).
* Effective as a delivery vehicle for anticancer drugs for treatment of metastasis in lymph nodes.

・Delivers siRNA, mRNA and other drugs targeting macrophages and DCs

・Oligomannose-coated liposomes are selectively taken up by macrophages and DCs, and effectively induce present encased antigens on MHC class I and class II　molecules.

※ Induce strong Th1 and Th2 immunological responses for application to vaccines for infectious diseases.
※ Induce antigen-specific CTL for application to cancer therapy products.
※ Proteins, peptides, DNA and mRNA can be embedded. Encased antigen, proteins, peptides, DNA, and mRNA can be embedded in liposomes.
※ Inhibit Th2 immunity and can be developed as allergy remedies.

Market Scale

・BMC will conduct “Nanotargeting Device Business” using the oligomannose-coated liposome technology.

Medicinal products to be developed under this project and the estimated scale of the domestic market for the meantime is as follows:
Anti-cancer drug-embedded liposome formulation………18 billion yen
Vaccines for infectious disease and cancer vaccines……40 billion yen
Allergy remedy products (hay fever) ……150 billion yen

・We will be the first to provide the market with “glycol-chain medicine” using the glycol-chain functions.

・We will provide treatments for recurrent ATLs, several chronic infections, and cancer diseases. We will also provide drugs and treatments for preventing these diseases.